Drugs in Cyclodextrin in Liposomes: How a Suitable Formulation of an Active Substance Can Improve Its Efficiency?

today’s cyclodextrin:
Drugs in Cyclodextrin in Liposomes: How a Suitable Formulation of an Active Substance Can Improve Its Efficiency?

Great paper from Prof Geraldine Gouhier, François Estour and colleagues from Université de Rouen on the design of new drug delivery systems.

Liposome formulations are pivotal in medicine for their ability to improve drug solubility, allowing for targeted delivery directly to disease sites, which minimizes side effects. They enable controlled and sustained release of medications, reducing dosage frequency. Their ability to encapsulate a variety of substances makes them versatile for different treatments, significantly reducing toxicity and enhancing the stability of drugs, especially sensitive biological compounds. This ensures a more effective and safer therapeutic approach.

Discover how the innovative “drug-in-cyclodextrin-in-liposomes” method is revolutionizing drug delivery! Enhancing drug stability & release, this latest review dives into how these nano-carriers improve the efficacy of various drugs. 🧬💊

Processes | Free Full-Text | Drugs in Cyclodextrin in Liposomes: How a Suitable Formulation of an Active Substance Can Improve Its Efficiency? (mdpi.com)

Methods for the treatment of chronic kidney disease

We are happy to announce the acceptance of a great patent from CarboHyde’s collaborator, Renatus, a pharmaceutical company focused on developing cyclodextrin-based cholesterol metabolism modulators. Renatus is a pharmaceutical company whose mission is to provide safe and effective treatment options for the treatment of numerous cholesterol-driven diseases such as chronic kidney disease, atherosclerosis, and Alzheimer’s diseases. The core technology of the company allows the normalization of cholesterol homeostasis by removal of excessive and toxic cholesterol within diseased cells without significant harmful effects on normal cells.

The lead asset RN-005 is a cholesterol metabolism modulator that has proven strong therapeutic efficacy in preclinical models of both diabetic kidney disease (DKD) and focal segmental glomerulosclerosis (FSGS) wherein dysregulated cholesterol metabolism causes progressive damage and loss of function in the kidney. The gamma-cyclodextrin oligomers are effective in cholesterol metabolism enhancement, cholesterol efflux, reducing inflammatory cytokine secretion, renal clearance of cholesterol, and/or reducing albuminuria. Therefore, the gamma-cyclodextrin oligomers can be used to treat or alleviate chronic kidney disease, symptoms thereof and/or complications related to chronic kidney disease.



today’s cyclodextrin:
The article on Captisol®, a solubilizing and stabilizing technology of Ligand Pharmaceuticals, highlights its evolution from uncertain beginnings to becoming a pharmaceutical industry staple, thanks to the perseverance of scientists and strategic partnerships, notably with Pfizer. Initially developed from the need for better drug formulation tools, Captisol has been integral in creating viable drug products, especially for poorly soluble and unstable molecules. Its proven safety, alongside innovations in production and application, has led to its inclusion in multiple FDA-approved drugs, with ongoing expansion into various administration routes and global regulatory acceptance​​.
#formulationdevelopment #drugdelivery

SOLUBILIZING & STABILIZING TECHNOLOGY – CAPTISOL® – Part Perseverance & Part Serendipity (drug-dev.com)

Combined use of nanobody, cyclodextrin and quercetin for protection from enveloped viruses

Fascinating antiviral application of cyclodextrins against SARS-COV2. You can find specific nanobodies against different target antigens such as the spike protein of the SARS-CoV-2 virus and or to the ACE2 receptor at the host cell surface, binds to the virus or the ACE2 receptor at the host cell plasma membrane, preventing entry of the SARS-CoV-2 virus. The nanobodies comprise a cyclodextrin; a zinc ionophore; a zinc-containing compound; and, benzalkonium.


Bicyclos International Workshop

On September 23, the Bicyclos consortium will meet in Budapest to share scientific results, presented mainly by seconded staff, promote discussions, and make a balance of the activity of the first year. We will meet near the Adina Apartment Hotel in Budapest.

Registration form: Bicyclos International Workshop on September 24-26, 2024 (google.com)

For the reservation: Adina Apartment Hotel Budapest | Best Rate Guaranteed (adinahotels.com)

Hydrogel composition for use in the treatment of articular disorders

Fascinating patent by Bernard MartelNicolas Blanchemain and colleagues presenting hydrogels on anionic cyclodextrin polymers and chitosan for use in the treatment of articular disorders. The hydrogel combines an analgesic action with a visco-supplementation (a lubricating effect).


Luminol-conjugated cyclodextrin biological nanoparticles for the treatment of severe burn-induced intestinal barrier disruption

Today’s cyclodextrin research highlights a promising new therapy for inflammation-related diseases and oxidative damage. Researchers have presented a new anti-inflammatory and antioxidant nanoparticle, LCD, which aims to protect against severe burn-induced intestinal injury. With traditional methods showing limitations, the application of nanoparticles like LCD could offer a much-needed protective strategy for the intestinal barrier.

Luminol-conjugated cyclodextrin biological nanoparticles for the treatment of severe burn-induced intestinal barrier disruption | Burns & Trauma | Oxford Academic (oup.com)

#burninjury #inflammation #antioxidant #nanotechnology

CarboHyde CEO presenting at CPHI North America

We are proud to announce that our CEO, Tamas Sohajda, will deliver a talk at CPHI North America in Philadelphia in May 2024.
You can learn more about the “Exploring Excipients” session and other speakers, Denise Reaves, M.S from Jurata Thin Film, and Björn-Hendrik Peters from Bristol Myers Squibb here: 

About the talk:
Explore novel applications in neurodegenerative diseases, gene therapy, and biotechnology, showcasing innovative structures, mechanisms, challenges, and results, with a focus on Alzheimer’s, Parkinson’s, rare genetic disorders, and potential expansion to longevity and infectious diseases, presenting a non-viral gene delivery platform and demonstrating CD utilization in vaccine adjuvants and biotechnological tools.

Resveratrol eye drops as well as preparation method and application

In some cases, the simplest, most straightforward ideas are the best. Why not develop an eye-drop based on cyclodextrin and resveratrol?  The resveratrol captured in an HPBCD inclusion complex has the advantages of simple preparation, short preparation period, no organic solvent residue, and no bacteriostatic agent. The lipoic acid added in the clathrate eye drops prepared by the invention cooperates with the resveratrol to play a better antioxidant effect so that the xerophthalmia is better relieved, and the treatment effect is achieved.

What to create similar solutions? Visit: www.carbohydesolutions.com – Carbohyde
Original paper: Espacenet – Resveratrol eye drops as well as preparation method and application thereof

Pharmaceutical composition and application patent

Today’s cyclodextrin is an interesting application proposed by RemeGen Biosciences, which uses methyl-BCD to remarkably improve the pharmaceutical effect of antibody-drug conjugates. By using CDs, the ACD load can be lower, thus greatly reducing the production cost and the treatment cost of a patient.
If you are interested in similar solutions, check out Formulation development – www.carbohydesolutions.com

Espacenet – Pharmaceutical composition and application thereof